http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8008274-B2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_47e6d64f3ca7f88ca5541672f0e21dca |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7084 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7072 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H19-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H21-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H19-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H19-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H19-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H19-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H21-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H19-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7072 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7084 |
| filingDate | 2009-05-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2011-08-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_533d2e18b4ad3f6bd76c6187fb8d9e2d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_396b0938ef7cb067291b01cd13f81ba0 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8d7e7d0a2a557b90c5dd5017c7d53e9d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_499a2bddf3538c3f8f82afb51c6e0e0b |
| publicationDate | 2011-08-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-8008274-B2 |
| titleOfInvention | P1-(2′-deoxycytidine 5′-)P4-(uridine 5′-)tetraphosphate, tetra-(alkali metal) salt, for treating sinusitis |
| abstract | The present invention provides a method of treating edematous retinal disorders. The method comprises administration of a pharmaceutical formulation comprising a hydrolysis-resistant P2Y receptor agonist to stimulate the removal of pathological extraneous fluid from the subretinal and retinal spaces and thereby reduce the accumulation of said fluid associated with retinal detachment and retinal edema. The P2Y receptor agonist can be administered with therapeutic and adjuvant agents commonly used to treat edematous retinal disorders. The present invention also provides a method of treating cystic fibrosis. The present invention also provides a method of treating sinusitis. The present invention further provides P 1 -(2′-deoxycytidine 5′-)P 4 -(uridine 5′-)tetraphosphate, tetra-(alkali metal) salts such as tetrasodium, tetralithium, tetrapotassium, and mixed (tetra-alkali metal) salts. The present further provides a pharmaceutical formulation comprising a P 1 -(2′-deoxycytidine 5′-)P 4 -(uridine 5′-)tetraphosphate, tetra-(alkali metal) salt, in a pharmaceutically acceptable carrier. |
| priorityDate | 1997-02-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 360.